Published in PLoS Med on March 12, 2013
HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. Lancet Infect Dis (2014) 3.65
HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr (2014) 2.43
Applying a PrEP Continuum of Care for Men Who Have Sex With Men in Atlanta, Georgia. Clin Infect Dis (2015) 2.08
Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco. PLoS Med (2014) 2.08
HIV risk and preventive interventions in transgender women sex workers. Lancet (2014) 1.67
Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection. J Infect Dis (2015) 1.45
Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review. HIV AIDS (Auckl) (2015) 1.31
Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. AIDS (2015) 1.30
Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda. J Int AIDS Soc (2015) 1.14
Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access. J Int AIDS Soc (2015) 1.09
Antiretrovirals for primary HIV prevention: the current status of pre- and post-exposure prophylaxis. Curr HIV/AIDS Rep (2015) 1.04
Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC Med (2014) 1.03
Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challenges. AIDS Patient Care STDS (2014) 1.02
Attitudes and perceptions of biomedical HIV prevention methods: voices from young men who have sex with men. Arch Sex Behav (2015) 1.00
Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics. PLoS One (2014) 0.97
HIV prevalence and factors associated with HIV infection among men who have sex with men in Cameroon. J Int AIDS Soc (2013) 0.94
Sources of HIV infection among men having sex with men and implications for prevention. Sci Transl Med (2016) 0.93
The promises and challenges of pre-exposure prophylaxis as part of the emerging paradigm of combination HIV prevention. J Int AIDS Soc (2015) 0.91
Accuracy of highly sexually active gay and bisexual men's predictions of their daily likelihood of anal sex and its relevance for intermittent event-driven HIV pre-exposure prophylaxis. J Acquir Immune Defic Syndr (2015) 0.89
Healthcare Access and PrEP Continuation in San Francisco and Miami Following the U.S. PrEP Demo Project. J Acquir Immune Defic Syndr (2016) 0.89
Pre-exposure prophylaxis for men and transgender women who have sex with men in Brazil: opportunities and challenges. J Int AIDS Soc (2015) 0.88
Acceptability of Condoms, Circumcision and PrEP among Young Black Men Who Have Sex with Men: A Descriptive Study Based on Effectiveness and Cost. Vaccines (Basel) (2014) 0.86
Dynamic Transmission Economic Evaluation of Infectious Disease Interventions in Low- and Middle-Income Countries: A Systematic Literature Review. Health Econ (2016) 0.85
Seasonal PrEP for partners of migrant miners in southern Mozambique: a highly focused PrEP intervention. J Int AIDS Soc (2015) 0.84
An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis. Trials (2016) 0.83
Lay Social Resources for Support of Adherence to Antiretroviral Prophylaxis for HIV Prevention Among Serodiscordant Couples in sub-Saharan Africa: A Qualitative Study. AIDS Behav (2015) 0.83
Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya. AIDS Behav (2015) 0.83
Pre-exposure prophylaxis in Southern Africa: feasible or not? J Int AIDS Soc (2015) 0.83
Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa. J Acquir Immune Defic Syndr (2016) 0.83
PrEP implementation in the Asia-Pacific region: opportunities, implementation and barriers. J Int AIDS Soc (2016) 0.82
Estimating the cost-effectiveness of pre-exposure prophylaxis to reduce HIV-1 and HSV-2 incidence in HIV-serodiscordant couples in South Africa. PLoS One (2015) 0.79
Modeling and Cost-Effectiveness in HIV Prevention. Curr HIV/AIDS Rep (2016) 0.79
Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study. J Acquir Immune Defic Syndr (2016) 0.78
Framing HIV Pre-Exposure Prophylaxis (PrEP) for the General Public: How Inclusive Messaging May Prevent Prejudice from Diminishing Public Support. AIDS Behav (2016) 0.77
Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa. Clin Infect Dis (2016) 0.77
HIV Incidence and Predictors of Incident HIV among Men Who Have Sex with Men Attending a Sexual Health Clinic in Melbourne, Australia. PLoS One (2016) 0.77
The European preexposure prophylaxis revolution. Curr Opin HIV AIDS (2016) 0.76
PrEP implementation research in Africa: what is new? J Int AIDS Soc (2016) 0.75
Deciphering the Effects of Injectable Pre-exposure Prophylaxis for Combination Human Immunodeficiency Virus Prevention. Open Forum Infect Dis (2016) 0.75
Contextual variations in costs for a community health strategy implemented in rural, peri-urban and nomadic sites in Kenya. BMC Public Health (2017) 0.75
Motives of Dutch men who have sex with men for daily and intermittent HIV pre-exposure prophylaxis usage and preferences for implementation: A qualitative study. Medicine (Baltimore) (2016) 0.75
Oral PrEP for HIV prevention. It works. J Virus Erad (2015) 0.75
PrEP Implementation Science: State-of-the-Art and Research Agenda. J Int AIDS Soc (2015) 0.75
PrEP as a feature in the optimal landscape of combination HIV prevention in sub-Saharan Africa. J Int AIDS Soc (2016) 0.75
The Potential Cost-Effectiveness of HIV Vaccines: A Systematic Review. Pharmacoeconom Open (2017) 0.75
Use of an HIV-risk screening tool to identify optimal candidates for PrEP scale-up among men who have sex with men in Toronto, Canada: disconnect between objective and subjective HIV risk. J Int AIDS Soc (2016) 0.75
PrEP awareness and decision-making for Latino MSM in San Antonio, Texas. PLoS One (2017) 0.75
The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States. Vaccines (Basel) (2017) 0.75
Generic substitution of antiretrovirals: patients' and health care providers' opinions. Int J STD AIDS (2017) 0.75
Combined interventions to reduce HIV incidence in KwaZulu-Natal: a modelling study. BMC Infect Dis (2017) 0.75
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med (2009) 65.36
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med (2012) 20.03
Preexposure prophylaxis for HIV infection among African women. N Engl J Med (2012) 15.28
Towards an improved investment approach for an effective response to HIV/AIDS. Lancet (2011) 11.89
Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ (1996) 10.84
Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep (2011) 4.85
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis (2009) 3.89
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
Preexposure prophylaxis and timed intercourse for HIV-discordant couples willing to conceive a child. AIDS (2011) 3.26
Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morb Mortal Wkly Rep (2012) 2.95
Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One (2007) 2.84
Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med (2011) 2.76
Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. AIDS (2010) 2.70
The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med (2012) 2.34
Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLoS One (2010) 2.30
A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS One (2012) 2.21
A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making (2002) 2.12
Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. PLoS One (2012) 2.09
Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics (2009) 1.97
Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One (2012) 1.84
The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS (2013) 1.81
The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis (2012) 1.80
The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK. Int J STD AIDS (2012) 1.59
Engaging healthcare providers to implement HIV pre-exposure prophylaxis. Curr Opin HIV AIDS (2012) 1.48
Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand. PLoS One (2011) 1.40
The real and the nominal? Making inflationary adjustments to cost and other economic data. Health Policy Plan (2000) 1.39
The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study. PLoS Med (2012) 1.35
Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J Acquir Immune Defic Syndr (2011) 1.31
The cost-effectiveness of pre-exposure prophylaxis in men who have sex with men in the United States: an epidemic model. J Acquir Immune Defic Syndr (2011) 1.14
Vaginal microbicides save money: a model of cost-effectiveness in South Africa and the USA. Sex Transm Infect (2010) 1.10
Views of policymakers, healthcare workers and NGOs on HIV pre-exposure prophylaxis (PrEP): a multinational qualitative study. BMJ Open (2012) 1.01
Preexposure chemoprophylaxis for HIV prevention. N Engl J Med (2011) 0.92
The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis. AIDS (2011) 0.86
Economic modeling of HIV treatments. Curr Opin HIV AIDS (2010) 0.80
Voluntary medical male circumcision: modeling the impact and cost of expanding male circumcision for HIV prevention in eastern and southern Africa. PLoS Med (2011) 7.56
The potential impact of male circumcision on HIV in Sub-Saharan Africa. PLoS Med (2006) 6.53
Transmission of HIV-1 infection in sub-Saharan Africa and effect of elimination of unsafe injections. Lancet (2004) 4.13
Achieving the WHO/UNAIDS antiretroviral treatment 3 by 5 goal: what will it cost? Lancet (2004) 3.14
The global impact of scaling up HIV/AIDS prevention programs in low- and middle-income countries. Science (2006) 2.76
Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. Lancet Infect Dis (2006) 2.48
Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res (2011) 2.45
Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J Clin Microbiol (2002) 2.18
Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. PLoS One (2012) 2.09
Back to basics in HIV prevention: focus on exposure. BMJ (2003) 1.99
Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test. J Clin Microbiol (2006) 1.96
Costs and efficiency of integrating HIV/AIDS services with other health services: a systematic review of evidence and experience. Sex Transm Infect (2011) 1.91
Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis. Eur Respir J (2012) 1.70
Vienna Declaration: a call for evidence-based drug policies. Lancet (2010) 1.52
Study protocol for the Integra Initiative to assess the benefits and costs of integrating sexual and reproductive health and HIV services in Kenya and Swaziland. BMC Public Health (2012) 1.51
Financing structural interventions: going beyond HIV-only value for money assessments. AIDS (2014) 1.45
The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study. PLoS Med (2012) 1.35
Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. J Int AIDS Soc (2010) 1.35
Feasibility, yield, and cost of active tuberculosis case finding linked to a mobile HIV service in Cape Town, South Africa: a cross-sectional study. PLoS Med (2012) 1.29
Voluntary medical male circumcision: an HIV prevention priority for PEPFAR. J Acquir Immune Defic Syndr (2012) 1.28
Positive impact of a large-scale HIV prevention programme among female sex workers and clients in South India. AIDS (2013) 1.26
Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus infection and cervical cytopathologic findings in HIV-positive and high-risk HIV-negative women. J Infect Dis (2013) 1.25
Confirmatory real-time PCR assay for human papillomavirus (HPV) type 52 infection in anogenital specimens screened for HPV infection with the linear array HPV genotyping test. J Clin Microbiol (2007) 1.20
Human papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: a review of recent developments. CMAJ (2003) 1.20
Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries. Clin Infect Dis (2008) 1.17
Understanding the modes of transmission model of new HIV infection and its use in prevention planning. Bull World Health Organ (2012) 1.14
Self-sampling is associated with increased detection of human papillomavirus DNA in the genital tract of HIV-seropositive women. Clin Infect Dis (2005) 1.13
The challenge of defining standards of prevention in HIV prevention trials. J Med Ethics (2010) 1.09
Complex emergencies, HIV, and substance use: no "big easy" solution. Subst Use Misuse (2006) 1.08
Genomic polymorphism of human papillomavirus type 52 predisposes toward persistent infection in sexually active women. J Infect Dis (2004) 1.03
Human papillomavirus type 16 (HPV-16) viral load and persistence of HPV-16 infection in women infected or at risk for HIV. J Clin Virol (2008) 1.03
Optimising the cost and delivery of HIV counselling and testing services in Kenya and Swaziland. Sex Transm Infect (2012) 1.00
Viral polymorphism in human papillomavirus types 33 and 35 and persistent and transient infection in the genital tract of women. J Infect Dis (2004) 0.98
Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review. Pharmacoeconomics (2015) 0.96
Ethical considerations in determining standard of prevention packages for HIV prevention trials: examining PrEP. Dev World Bioeth (2013) 0.96
Introduction: Addressing the vulnerability of young women and girls to stop the HIV epidemic in southern Africa. AIDS (2008) 0.96
Polymorphism of human papillomavirus type 31 isolates infecting the genital tract of HIV-seropositive and HIV-seronegative women at risk for HIV infection. J Med Virol (2005) 0.96
Molecular analysis of human papillomavirus type 52 isolates detected in the genital tract of human immunodeficiency virus-seropositive and -seronegative women. J Infect Dis (2003) 0.95
Real-time PCR assays using internal controls for quantitation of HPV-16 and beta-globin DNA in cervicovaginal lavages. J Virol Methods (2003) 0.94
Prevalence of selective inhibition of HPV-16 DNA amplification in cervicovaginal lavages. J Med Virol (2004) 0.92
High levels of HPV-16 DNA are associated with high-grade cervical lesions in women at risk or infected with HIV. AIDS (2005) 0.91
High level of correlation of human papillomavirus-16 DNA viral load estimates generated by three real-time PCR assays applied on genital specimens. Cancer Epidemiol Biomarkers Prev (2005) 0.91
The costs of HIV prevention for different target populations in Mumbai, Thane and Bangalore. BMC Public Health (2011) 0.91
The impact of HIV/SRH service integration on workload: analysis from the Integra Initiative in two African settings. Hum Resour Health (2014) 0.89
Embracing different approaches to estimating HIV incidence, prevalence and mortality. AIDS (2014) 0.88
Polymorphism of the capsid L1 gene of human papillomavirus types 31, 33, and 35. J Med Virol (2010) 0.88
Paying girls to stay in school: a good return on HIV investment? Lancet (2012) 0.87
Introducing a model of cardiovascular prevention in Nairobi's slums by integrating a public health and private-sector approach: the SCALE-UP study. Glob Health Action (2013) 0.86
AIDS in Africa. Lancet (2002) 0.85
Polymorphism of the L1 capsid gene and persistence of human papillomavirus type 52 infection in women at high risk or infected by HIV. J Acquir Immune Defic Syndr (2007) 0.84
Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users. PLoS One (2011) 0.83
Measuring safety and efficiency in the operating room: development and validation of a metric for evaluating task execution in the operating room. J Am Coll Surg (2013) 0.82
Influence of human papillomavirus type 16 (HPV-16) E2 polymorphism on quantification of HPV-16 episomal and integrated DNA in cervicovaginal lavages from women with cervical intraepithelial neoplasia. J Gen Virol (2008) 0.79
Human papillomavirus type 16 viral load is higher in human immunodeficiency virus-seropositive women with high-grade squamous intraepithelial lesions than in those with normal cytology smears. J Clin Microbiol (2004) 0.79
Human papillomavirus type 56 polymorphism in Canadian women with and without cervical lesions. J Clin Virol (2013) 0.79
The health system burden of chronic disease care: an estimation of provider costs of selected chronic diseases in Uganda. Trop Med Int Health (2015) 0.79
Building global capacity for patient safety: a training program for surgical safety research in developing and transitional countries. Int J Surg (2012) 0.79
Tuberculosis control in crisis: economic honesty and comparative effectiveness. Int J Tuberc Lung Dis (2012) 0.78
Asking the right questions: developing evidence-based strategies for treating HIV in women and children. BMC Public Health (2011) 0.78
Sex, drugs, and gender? High time for lived experience to inform action. Int J Drug Policy (2008) 0.78
Empirical validation of the UNAIDS Spectrum model for subnational HIV estimates: case-study of children and adults in Manicaland, Zimbabwe. AIDS (2017) 0.76
VMMC Devices-Introducing a New Innovation to a Public Health Intervention. J Acquir Immune Defic Syndr (2016) 0.75
Correction: Voluntary Medical Male Circumcision for HIV Prevention: New Mathematical Models for Strategic Demand Creation Prioritizing Subpopulations by Age and Geography. PLoS One (2016) 0.75
[Male circumcision--an evidence-based preventive measure]. Ugeskr Laeger (2008) 0.75
Correction: Impact and Cost of Scaling Up Voluntary Medical Male Circumcision for HIV Prevention in the Context of the New 90-90-90 HIV Treatment Targets. PLoS One (2016) 0.75
Ano-genital human papillomavirus type 97 infection is detected in Canadian men but not women at risk or infected with the human immunodeficiency virus. Virol J (2012) 0.75
Research in action: from AIDS to global health to impact. A symposium in recognition of the scientific contributions of Professor Joep Lange. Antivir Ther (2015) 0.75